All In Biotech

Drug Trial Radar · NCT05174221

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Aug 16, 2022

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will have two parts. The main aims are to: * check the side effects from mezagitamab. * check for long-term side effects from mezagitamab. Before starting the study, participants will be asked to provide a 24-hour urine sample. A few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When treatment has ended, there will be a 24-week follow-up period. Participants who receive benefit from the treatment may continue in the second part of the study where they will be monitored for up to 96 weeks and possibly retreated for another 24 weeks.

Conditions

  • Kidney Disease
  • Glomerulonephritis

Interventions

  • MezagitamabDrug

    TAK-079 subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Percentage of Participants With one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher TEAEs, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Mezagitamab DiscontinuationTime frame: Up to Week 48
  2. LTE Observation Period: Percentage of Participants With one or More TEAEs, Grade 3 or Higher TEAEs and SAEsTime frame: Up to Week 96
  3. LTE Retreatment Period: Percentage of Participants With one or More TEAEs, SAEs, Grade 3 or Higher TEAEs and AEs leading to Mezagitamab DiscontinuationTime frame: Retreatment Week 0 to 48

Locations

26 sites in 11 countries. Site status is shown where the registry gives one.

  • Amicis Research Center - Northridge - Nordhoff

    Northridge, California

  • Boise Kidney and Hypertension Institute - Frenova

    Nampa, Idaho

  • NorthShore University HealthSystem

    Evanston, Illinois

  • Core Research Group

    Milton, Queensland, Australia

  • Monash Health, Monash Medical Centre

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Semmelweis Egyetem

    Budapest, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont

    Szeged, Csongrád megye, Hungary

  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia

    Brescia, Lombardy, Italy

  • Kasugai Municipal Hospital

    Kasugai-Shi, Aiti, Japan

  • Fujita Health University Hospital

    Toyoake-shi, Aiti, Japan

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan

  • Sapporo City General Hospital

    Sapporo, Hokkaido, Japan

  • National University Hospital- Singapore

    Singapore, Singapore

  • Ajou University Hospital

    Suwon, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Hospital Universitario Vall d'Hebron - PPDS

    Barcelona, Spain

  • Fundacio Puigvert

    Barcelona, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • Taipei Medical University Shuang Ho Hospital

    New Taipei City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Hull Royal Infirmary

    Hull, United Kingdom

  • Leicester General Hospital

    Leicester, Leicestershire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.